Liraglutide in Newly Onset Type 1 Diabetes.

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial of Liraglutide Treatment in Subjects With Newly Diagnosed Type 1 Diabetes.

The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.

Inclusion Criteria:

• Type 1 diabetes according to WHO criteria diagnosed ≤ 6 weeks before visit 0
• Age 18 - 40 years - both inclusive
• Postprandial C-peptide > 0.2 nmol/l following sustacal meal test
• Able to understand the written patient information and to give informed consent

Exclusion Criteria:

• Type 2 diabetes
• Body mass index <20 kg/m2
• Pregnancy or unwillingness to use safe contraceptives
• Compromised kidney function (eGFR < 60 ml/min/1,73m2), dialysis or kidney transplantation at visit 0
• Liver disease with elevated plasma alanine aminotransferase (ALT) > three times the upper limit of normal at visit 0